Export Compliance Daily is a service of Warren Communications News.
Subscriber Login
“AbbVie” articles
to
articlessource documents
Refine Search

Search Primer

Term list: Separate terms with spaces, not commas or semicolons.

Multi-word term: Place inside quotes to ensure an exact match (e.g. "China import").

Acronyms: Use all capital letters to ensure the search is not looking for that letter sequence instead.

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., +CBP).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., -ruling).

Singular form: Always use the singular form when doing multi-word terms (e.g. "russian export control" instead of "russian export controls").

Shortest word form: When you have different word forms in a quoted (multi-word) term, you want to only include the shortest version if it is the last part of the expression (e.g., "entity list" instead of "entity listing" or "entity listed").

ITC Launches Section 337 Investigation on Antibody Drugs
December 19, 2025 |AD/CV - Patent

The International Trade Commission began a Section 337 investigation on allegations that ProfoundBio, Genmab and their subsidiaries are importing and selling antibody drugs that infringe patents held by AbbVie Inc., and ImmunoGen, Inc. (ITC Inv. No. 337-TA-1466), it said in a notice to be published Dec. 22.

ITC Seeks Comments on Section 337 Complaint on Antibody Drugs
November 20, 2025 |AD/CV - Patent

The International Trade Commission seeks comments by Dec. 1 on a Section 337 complaint alleging that imports of antibody drugs infringe patents held by AbbVie Inc., and ImmunoGen, Inc., it said in a notice to be published Nov. 21 in the Federal Register. According to the complaint, AbbVie is seeking a limited exclusion order and cease and desist orders against ProfoundBio, Genmab and their subsidiaries to bar from entry "certain antibody drug conjugates products and components thereof and products containing the same" that violate their patents. AbbVie said that its product ELAHERE, is "a first-in-class ADC approved to treat adult patients with certain ovarian, fallopian tube, and primary peritoneal cancers."

Trump Asks Pharma Companies to Lower Prices
July 31, 2025 |White House

President Donald Trump sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi, posting several of them online, telling them they should, within 60 days, set prices for Medicaid at the same level as the cheapest price their drugs are sold in a developed country; contract that when new drugs are launched, Medicaid, Medicare and private insurers all get that global low price; and allow direct-to-consumer sales for high-volume drugs, as long as those sales are at the same price as to insurers.